On October 10, 2008, we convened the First Annual American Health & Drug Benefits Summit on Healthcare Stakeholder Integration—The Return to Deep Science: Pharmaceutical Research & Development in a Value-Based Healthcare System. The proceedings are published in a special supplement accompanying this issue of the journal. The summit brought together leaders from many sectors to evaluate the prospects for the future of healthcare innovation, which is fundamental to the viability of the healthcare system.
Well established is the fact that prescription copayments (ie, the price paid by members) and how they are structured play a role in influencing the demand for prescription medications.1,2 Many plan sponsors are banking on the tenet of price responsiveness by lowering copayments to increase utilization of select chronic therapies.
Prescription Copay Reduction Program for Diabetic Employees: Impact on Medication Compliance and Healthcare Costs and Utilization
Kavita V. Nair, PhD, Kerri Miller, PharmD, BCPS, Joseph Saseen, PharmD, FCCP, BCPS, Pamela Wolfe, MS, Richard Read Allen, MS, Jinhee Park, CPhil, Ma, MS
For employers, the underlying premise of benefit design is to provide quality healthcare services to their employees. Although the cost of providing healthcare benefits is a key consideration, employers balance this consideration against employee satisfaction and retention as well as productivity.1 The concept of a value-based benefit design (VBBD) has emerged over the past decade as a strategy to meet this objective.
Improved Clinical Outcomes the True Value of Copay Reductions for Diabetic Employees, Despite Increased Overall Costs
Partial Compliance with Antipsychotics Increases Mental Health Hospitalizations in Schizophrenic Patients: Analysis of a National Managed Care Database
Medication noncompliance is considered to be the single most important factor leading to relapse among patients with schizophrenia.1 One meta-analysis of maintenance antipsychotic treatment found that noncompliance causes about 40% of relapses.2 The advent of newer, second-generation oral antipsychotics has had a greater impact on efficacy than on adherence.
Encouraging Compliance Key for Positive Outcomes in Schizophrenia/Chronic Diseases
Alzheimer's disease (AD), the most common cause of dementia, increases in prevalence exponentially with age, and the trend of growing incidence of the disease is likely to continue in the United States. Alzheimer's dementia is a common, acquired disorder that is manifested as slowly progressive memory loss with at least 1 cognitive dysfunction (ie, aphasia, apraxia, agnosia, or executive dysfunction) and resulting in impaired occupational and social performance.
The Challenge of Value-Based Benefit Design in Alzheimer's Disease
Ateam of experts from the Centers for Medicare & Medicaid Services (CMS) released new data in the early days of the new year, detailing the most recent national health spending data for 2007, based on Medicare and Medicaid data, the Census Bureau's data, private health insurance filings with state commissioners, provider surveys, and many other sources.1 These new data from the National Health Expenditure Accounts show that the rate of increase in healthcare spending in the United States grew in 2007 at the lowest rate since 1998.1
Adherence to statin therapy is known to be poor, estimated to be about 50% at 12 months after initiation, even among patients with good insurance benefits, said Sebastian Schneeweiss, MD, Associate Professor of Medicine and Epidemiology at Harvard Medical School in Boston, MA, during the American Heart Association 2008 Scientific Sessions.
Results 1 - 7 of 7